519 results on '"Kümmel, S."'
Search Results
2. EFFECT OF DIBUTYLTIN DICHLORIDE ON LIPASE AND AMYLASE ACTIVITY IN SERUM AND PANCREAS OF RATS
3. Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522
4. Traditionelle chinesische Medizin in der integrativen Onkologie
5. Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2− early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2− trial
6. Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE
7. Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study
8. Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patients
9. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study
10. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results from GeparSixto
11. Can contemporary trials of chemotherapy for HER2-negative metastatic breast cancer detect overall survival benefit?
12. Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective EvAluate-TM study
13. Budget impact analysis of gene expression tests to aid therapy decisions for breast cancer patients in Germany
14. Influence of patient and tumor characteristics on early therapy persistence with letrozole in postmenopausal women with early breast cancer: results of the prospective Evaluate-TM study with 3941 patients
15. Time trends (2006–2015) of quality indicators in EUSOMA-certified breast centres
16. De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel
17. Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial
18. Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer
19. Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer – The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29)
20. 196P Efficacy and safety of first-line (1L) ribociclib (RIB) + letrozole (LET) in patients (pts) with de novo metastatic disease and late recurrence from (neo)adjuvant therapy (tx) in MONALEESA (ML)-2
21. 120TiP Premenopausal women with breast cancer optimally treated with OFS (PROOFS)
22. 18P A translational project of the WSG-ADAPT-TN trial demonstrates immunomodulatory and anti-viral defense gene networks predicting pathological complete response (pCR) and survival after de-escalated neoadjuvant chemotherapy (NACT) in early triple-negative breast cancer (eTNBC)
23. Lebensstilfaktoren und Komplementärmedizin beim Mammakarzinom
24. Mind-Body-Medizin in der integrativen Onkologie: Studienlage und Einsatzgebiete
25. Using the framework of corporate culture in “mergers” to support the development of a cultural basis for integrative medicine – guidance for building an integrative medicine department or service
26. Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40—GeparQuattro)
27. Standards in der adjuvanten Systemtherapie des Mammakarzinoms
28. Role of serum concentration of VEGFR1 and TIMP2 on clinical outcome in primary cervical cancer: Results of a companion protocol of the randomized, NOGGO–AGO phase III adjuvant trial of simultaneous cisplatin-based radiochemotherapy vs. carboplatin and paclitaxel containing sequential radiotherapy
29. Additional prognostic value of lymph node ratio over pN staging in different breast cancer subtypes based on the results of 1,656 patients
30. A randomized phase III adjuvant study in high-risk cervical cancer: simultaneous radiochemotherapy with cisplatin (S-RC) versus systemic paclitaxel and carboplatin followed by percutaneous radiation (PC-R): a NOGGO-AGO Intergroup Study
31. Pre-pectoral mesh supported breast reconstruction: 24 months Patient-Reported-Outcome Analysis of the international TiLOOP-PRO-Pocket-Trial.
32. Analyzing Excitation-Energy Transfer Based on the Time-Dependent Density Functional Theory in Real Time.
33. VP7-2021: KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC
34. Epirubicin and cyclophosphamide versus epirubicin and docetaxel as first-line therapy for women with metastatic breast cancer: final results of a randomised phase III trial
35. New method for producing power electronic circuit boards by cold-gas spraying and investigation of adhesion mechanisms
36. Management der Axilla beim primär operablen Mammakarzinom
37. A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines
38. Pegfilgrastim ± ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study
39. Surgical treatment of primary breast cancer in the neoadjuvant setting
40. Pflegekonzept in der Integrativen Onkologie: ID 196
41. Run-in phase of prospective WSG ADAPT HR+/HER2- trial demonstrates feasibility of early endocrine sensitivity prediction by Recurrence Score and conventional parameters in clinical routine.: ID 455
42. Non-pegylated liposomal doxorubicin and docetaxel in metastatic breast cancer: final results of a phase II trial
43. Adjuvante Therapie beim Zervixkarzinom
44. The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use
45. Collectivity in the optical response. of small metal clusters
46. Static electric dipole polarizabilities of Na clusters
47. Frequencies, times, and forces in the dynamics of Na clusters
48. Structure and optic response of the Na9 + and Na55 + clusters
49. Impact of the Oncotype DX® Recurrence Score® Assay on therapy recommendations for ER-positive (ER+), node negative (N0) and node positive (N+) early breast cancer - Results of an interim analysis of the German decision impact study: V444
50. Optimierung des Therapiemanagements gynäkologischer Malignome durch interdisziplinäre und intersektorale Online-Tumorkonferenzen - Ein Projekt der integrierten Versorgung und Versorgungsforschung: PO015
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.